Dimercaprol
FDA-approved product (injectable, injection), marketed as Bal.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Dimercaprol. Its therapeutic class is shown instead.
- WHO therapeutic group
- Antidotes
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Dimercaprol, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA15.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli13.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis16.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dimercaprol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057
NCT01587807 · start 2012-03-28
Registered record
- Registry ID
- NCT01587807
- Conditions
- Respiratory Disorders
- Interventions
- GSK1995057; bronchoalveolar lavage; LPS; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-03-28
- Completion
- 2012-11-19
- Enrolment
- 53
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRespiratory DisordersInterventionGSK1995057; bronchoalveolar lavage; LPS; PlaceboPhasePhase 1Registry statusCompletedInduced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis
NCT01011543 · start 2009-08
Registered record
- Registry ID
- NCT01011543
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Diagnostic techniques in pulmonary tuberculosis
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-08
- Completion
- 2015-12
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary TuberculosisInterventionDiagnostic techniques in pulmonary tuberculosisPhaseNot applicableRegistry statusCompletedTransbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy
NCT00917137 · start 2008-07
Registered record
- Registry ID
- NCT00917137
- Conditions
- Pulmonary Nodule; Pulmonary Mass
- Interventions
- TBNA + transbronchial lung biopsy + bronchial washing
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2010-06
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Nodule; Pulmonary MassInterventionTBNA + transbronchial lung biopsy + bronchial washingPhaseNot recordedRegistry statusCompletedDiagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples
NCT01430663 · start 2007-04
Registered record
- Registry ID
- NCT01430663
- Conditions
- Invasive Aspergillosis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2011-02
- Enrolment
- 87
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInvasive AspergillosisInterventionNot recordedPhaseNot recordedRegistry statusCompletedAnalysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
NCT00001541 · start 1996-04
Registered record
- Registry ID
- NCT00001541
- Conditions
- Inflammation; Vasculitis; Wegener's Granulomatosis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1996-04
- Completion
- 2003-01
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammation; Vasculitis; Wegener's GranulomatosisInterventionNot recordedPhaseNot recordedRegistry statusCompleted